~11 spots leftby Dec 2026

Oral Fiber Supplementation for Blood Cancers

DF
Overseen byDavid Fredricks
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Fred Hutchinson Cancer Research Center
Disqualifiers: Major psychiatric diagnosis, Pregnancy, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical trial examines sustained oral fiber supplementation for patients undergoing donor stem cell transplantation for hematological malignancies. Patients undergoing donor stem cell transplantation often develop oral and gastrointestinal damage from chemotherapy, radiotherapy, or graft-versus-host disease. Oral fiber nutrition support may improve overall nutrition, support a normal gut microbiome (bacteria that live in the gut) and/or improve gut function in patients undergoing stem cell transplants.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Kate Farms 1.0, Oral Fiber Supplement, Nutritional Supplement Drink for blood cancers?

The research on oat-based beverages suggests that they are well-accepted by cancer patients and can be used to improve their nutritional intake, which is often inadequate. This indicates that similar nutritional supplements, like Kate Farms 1.0, could potentially support patients with blood cancers by enhancing their overall nutrition.12345

Is oral fiber supplementation generally safe for humans?

Dietary fiber intake is generally considered safe and provides health benefits, such as reducing the risk of heart disease, stroke, and certain gastrointestinal issues. Increasing fiber intake can also help with weight loss and improve blood sugar control in both diabetic and non-diabetic individuals.23678

How does the treatment Kate Farms 1.0 differ from other treatments for blood cancers?

Kate Farms 1.0 is unique because it is an oral fiber nutritional supplement, which may offer supportive care by potentially improving gut health and nutrient intake, unlike traditional cancer treatments that focus on directly targeting cancer cells.2891011

Research Team

DF

David Fredricks

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Eligibility Criteria

This trial is for adults who are about to have a stem cell transplant for blood cancer and will be hospitalized for it. They must understand the study and agree to participate. People with major uncontrolled psychiatric issues, those already on tube or IV nutrition, or with physical barriers to nasal feeding tubes can't join.

Inclusion Criteria

I am 18 years old or older.
I am scheduled for a stem cell transplant that will require a hospital stay.
I am scheduled for a stem cell transplant that requires a hospital stay.
See 1 more

Exclusion Criteria

Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team
I cannot have a feeding tube placed through my nose due to physical restrictions.
I am currently on tube feeding or IV nutrition.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-treatment

Participants receive fiber supplementation orally or enterally starting 14 to 5 days prior to standard of care conditioning chemotherapy

1-2 weeks

Treatment

Participants continue fiber supplementation until discharge from the hospital, with possible parenteral or enteral nutrition support

Until hospital discharge

Follow-up

Participants are monitored for safety and effectiveness after treatment, with follow-up visits at days 42, 60, and 90 post-transplant

Up to 90 days following transplant
3 visits (in-person)

Treatment Details

Interventions

  • Kate Farms 1.0 (Dietary Supplement)
  • Nutritional Supplement Drink (Dietary Supplement)
  • Standard of Care Nutritional Support (Dietary Supplement)
Trial OverviewThe study is testing if giving nutritional support through a nose-to-gut feeding tube early on helps patients better tolerate their stem cell transplant compared to standard care. It includes using Kate Farms formula and tracking patient experiences via surveys.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Supportive care (Fiber) [Current study activity]Experimental Treatment5 Interventions
Patients receive fiber supplementation PO or enterally starting 14 to 5 days prior to standard of care conditioning chemotherapy and continuing until discharge from the hospital. Stool will be collected at different time points throughout the study. Patients may also undergo blood sample collection throughout the study.
Group II: Arm I (enteral nutrition) [Discontinued in January 2024]Experimental Treatment2 Interventions
Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
Group III: Arm II (standard of care) [Discontinued in January 2024]Active Control2 Interventions
Patients receive standard of care nutritional support.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Fred Hutchinson Cancer Research Center

Lead Sponsor

Trials
444
Recruited
148,000+
Dr. Nancy Davidson profile image

Dr. Nancy Davidson

Fred Hutchinson Cancer Research Center

Chief Medical Officer since 2020

MD from Harvard Medical School

Dr. Thomas J. Lynch Jr. profile image

Dr. Thomas J. Lynch Jr.

Fred Hutchinson Cancer Research Center

Chief Executive Officer since 2020

MD from Yale University, BA from Yale College

Fred Hutchinson Cancer Center

Lead Sponsor

Trials
583
Recruited
1,341,000+
Dr. W. Thomas Purcell profile image

Dr. W. Thomas Purcell

Fred Hutchinson Cancer Center

Chief Medical Officer since 2022

MD from Emory University School of Medicine, MBA from University of Chicago

Dr. Thomas J. Lynch Jr. profile image

Dr. Thomas J. Lynch Jr.

Fred Hutchinson Cancer Center

Chief Executive Officer since 2020

MD from Yale School of Medicine

Findings from Research

Oat-based beverages were well accepted by both cancer patients and healthy participants, indicating their potential as nutritious products for improving nutrient intake in cancer care.
Patients with cancer found the beverages slightly too sweet but appreciated the flavor intensity, suggesting that oat-based drinks can be tailored to meet their preferences while also being fortified with nutrients like protein and fish oil.
Acceptance of oat-based beverages tailored for patients with cancer.Enriquez Fernandez, BE., Klassen, P., Mazurak, V., et al.[2021]
While some studies suggest a negative association between dietary fiber intake and colon cancer rates, the evidence remains inconsistent and inconclusive, with some studies even indicating a potential positive association in certain populations.
Despite the lack of definitive proof that fiber protects against colorectal cancer, dietary guidelines promoting increased consumption of fiber-rich foods like cereals, fruits, and vegetables are still recommended as they are unlikely to cause harm and may contribute to overall health.
Fiber intake in different populations and colon cancer risk.McKeown-Eyssen, GE.[2019]
In the Wheat Bran Fiber trial involving participants with a baseline average fiber intake of 17.5 grams per day, no significant effect of high-fiber supplementation on the recurrence of colorectal adenomas was observed.
Baseline fiber intake did not influence adenoma recurrence rates, nor did it modify the effects of the treatment groups, indicating that the fiber levels consumed may have been adequate to prevent recurrence.
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial.Jacobs, ET., Giuliano, AR., Roe, DJ., et al.[2019]

References

Acceptance of oat-based beverages tailored for patients with cancer. [2021]
Fiber intake in different populations and colon cancer risk. [2019]
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. [2019]
A Preparatory Study for a Randomized Controlled Trial of Dietary Fiber Intake During Adult Pelvic Radiotherapy. [2023]
Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trial. [2017]
Health benefits of dietary fiber. [2023]
Different Sources of Fiber Intake and Risk of 17 Specific Cancers and All Cancers Combined: Prospective Study of 364,856 Participants in UK Biobank. [2023]
Colonic fermentation and markers of colorectal-cancer risk. [2018]
Influence of wheat bran on NMU-induced mammary tumor development, plasma estrogen levels and estrogen excretion in female rats. [2019]
Dietary fiber and breast cancer. [2022]
[Systematic Review of Case Reports on the Adverse Events Due to Health Food Intake by Cancer Patients]. [2020]